Nami Kakuta1, Katsuyoshi Kume1, Eisuke Hamaguchi1, Rie Tsutsumi2, Naoji Mita1, Katsuya Tanaka1, Yasuo M Tsutsumi3. 1. Department of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. 2. Department of Nutrition, Tokushima University, Tokushima, Japan. 3. Department of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. tsutsumi@tokushima-u.ac.jp.
Abstract
PURPOSE:Postoperative nausea and vomiting (PONV) is the most common complication after surgery, and opioid administration increases its incidence. We compared the preventive effects of fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, with those of ondansetron on PONV in patients who underwent lower limb surgery with postoperative epidural opioid administration. METHODS: This prospective, double-blind, randomized study included 38 patients who underwent lower limb surgery. They were randomly allocated to receive intravenous fosaprepitant 150 mg (n = 19; NK1 group) or ondansetron 4 mg (n = 19; ONS group) before general anesthesia. All patients received postoperative epidural fentanyl for pain control. The incidence of nausea and vomiting, complete response rate (no vomiting and no rescue antiemetic use), rescue antiemetic use, nausea score (0-3), and visual analog scale (VAS 0-10) score for pain were recorded at 2, 24, and 48 h after surgery. RESULTS: No patient in the NK1 group experienced vomiting (0%) during the first 24 and 48 h after surgery, while 5 of 19 (26%) patients in the ONS group experienced this complication, indicating a significant difference between groups. There were no significant differences in the incidence of PONV, complete response rate, rescue antiemetic use, nausea score, and VAS score for pain between the NK1 and ONS groups during the study period. CONCLUSIONS: Fosaprepitant was more effective than ondansetron in decreasing the incidence of vomiting after lower limb surgery with postoperative opioid administration. Meanwhile, fosaprepitant was not inferior to ondansetron in decreasing the incidence and severity of PONV.
RCT Entities:
PURPOSE:Postoperative nausea and vomiting (PONV) is the most common complication after surgery, and opioid administration increases its incidence. We compared the preventive effects of fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, with those of ondansetron on PONV in patients who underwent lower limb surgery with postoperative epidural opioid administration. METHODS: This prospective, double-blind, randomized study included 38 patients who underwent lower limb surgery. They were randomly allocated to receive intravenous fosaprepitant 150 mg (n = 19; NK1 group) or ondansetron 4 mg (n = 19; ONS group) before general anesthesia. All patients received postoperative epidural fentanyl for pain control. The incidence of nausea and vomiting, complete response rate (no vomiting and no rescue antiemetic use), rescue antiemetic use, nausea score (0-3), and visual analog scale (VAS 0-10) score for pain were recorded at 2, 24, and 48 h after surgery. RESULTS: No patient in the NK1 group experienced vomiting (0%) during the first 24 and 48 h after surgery, while 5 of 19 (26%) patients in the ONS group experienced this complication, indicating a significant difference between groups. There were no significant differences in the incidence of PONV, complete response rate, rescue antiemetic use, nausea score, and VAS score for pain between the NK1 and ONS groups during the study period. CONCLUSIONS: Fosaprepitant was more effective than ondansetron in decreasing the incidence of vomiting after lower limb surgery with postoperative opioid administration. Meanwhile, fosaprepitant was not inferior to ondansetron in decreasing the incidence and severity of PONV.
Authors: Kenneth C Lasseter; Jay Gambale; Bo Jin; Art Bergman; Marvin Constanzer; James Dru; Tae H Han; Anup Majumdar; Judith K Evans; M Gail Murphy Journal: J Clin Pharmacol Date: 2007-05-24 Impact factor: 3.126
Authors: Steven Grunberg; Daniel Chua; Anish Maru; José Dinis; Suzanne DeVandry; Judith A Boice; James S Hardwick; Elizabeth Beckford; Arlene Taylor; Alexandra Carides; Fausto Roila; Jørn Herrstedt Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Tong J Gan; Christian C Apfel; Anthony Kovac; Beverly K Philip; Neil Singla; Harold Minkowitz; Ashraf S Habib; Jennifer Knighton; Alexandra D Carides; Hong Zhang; Kevin J Horgan; Judith K Evans; Francasca C Lawson Journal: Anesth Analg Date: 2007-05 Impact factor: 5.108
Authors: M F Barbe; B A Hilliard; P W Fisher; A R White; S P Delany; V J Iannarone; M Y Harris; M Amin; G E Cruz; S N Popoff Journal: Connect Tissue Res Date: 2019-08-23 Impact factor: 3.417
Authors: Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke Journal: Cochrane Database Syst Rev Date: 2020-10-19